• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Did New FSANZ Soy Protein Heart Health Claim Just Shift International Flavors & Fragrances' (IFF) Investment Narrative?

    Simply Wall St·04/02/2026 03:31:19
    Listen to the news
    • International Flavors & Fragrances recently announced that Food Standards Australia New Zealand approved a heart health claim for isolated soy protein, allowing foods in Australia and New Zealand delivering 20–25 grams daily to promote benefits for blood cholesterol as part of a balanced diet.
    • This regulatory milestone expands the scope for IFF’s SOLAE SUPRO soy protein portfolio in plant-based and functional foods, giving brands new ways to link clinically supported heart health benefits with products consumers already seek for taste and convenience.
    • We’ll now examine how this new FSANZ-approved heart health claim for isolated soy protein could influence International Flavors & Fragrances’ investment narrative.

    The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 22 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

    International Flavors & Fragrances Investment Narrative Recap

    To own International Flavors & Fragrances, you need to believe its refocused, higher margin ingredients portfolio can return to consistent profitability while managing lingering pressure in Food Ingredients and Fragrance Ingredients. The new FSANZ heart health claim supports that story at the margin by reinforcing IFF’s health and science credentials, but it does not change the near term catalyst around execution in core segments or the key risk of continued weakness in certain end markets.

    Among recent announcements, the March 2026 expansion of fermentation and application capabilities in Latin America is especially relevant. Together with the soy protein health claim in Australia and New Zealand, it underlines IFF’s effort to align its Taste and Health & Biosciences businesses with demand for functional, better for you products while increasing its presence in faster growing regions that management has highlighted as important to future volume growth and mix improvement.

    Yet despite these positives, investors should still pay attention to how prolonged softness in key regions and the underperforming Food Ingredients segment could...

    Read the full narrative on International Flavors & Fragrances (it's free!)

    International Flavors & Fragrances' narrative projects $11.4 billion revenue and $784.4 million earnings by 2028.

    Uncover how International Flavors & Fragrances' forecasts yield a $90.71 fair value, a 25% upside to its current price.

    Exploring Other Perspectives

    IFF 1-Year Stock Price Chart
    IFF 1-Year Stock Price Chart

    Compared with the baseline view, the most optimistic analysts expect revenue of about US$11.6 billion and earnings of roughly US$1.2 billion by 2028, so if you believe broad based growth in natural, health focused ingredients and margin expansion is achievable, this new soy protein claim and the risk of higher regulatory costs could both shift how you think about which scenario feels closer to reality.

    Explore 3 other fair value estimates on International Flavors & Fragrances - why the stock might be worth as much as 63% more than the current price!

    The Verdict Is Yours

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    Curious About Other Options?

    Our top stock finds are flying under the radar-for now. Get in early:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.